Daily close, T-120 (10/14/24) through T+5. Run-up high $156.62 on 10/24/24, low $126.4 on 11/28/24 (T-120 to T-1). FDA decision 3/31/25. Historical price action, not a forecast.
Positioning before the decision
On Mar 17, 2025, 14 days before the decision date, at-the-money options priced a move of ±4.0% through Apr 4, 2025 (the first listed expiry after the decision; ATM implied volatility 22%). The stock closed -0.4% at the first close across the decision and -7.2% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Yes. The FDA approved the application for IMFINZI (durvalumab) on March 31, 2025. The primary source is linked on this page.
What was IMFINZI (durvalumab) under FDA review for?
The application covered Muscle-invasive bladder cancer (MIBC). The FDA approved the application on March 31, 2025.
How did AZN stock react to the FDA decision?
On the decision day AZN moved -0.1%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.